A multicenter, randomized, and double-blind phase IV clinical trial to compare the efficacy and safety of fixed-dose combinations of amlodipine orotate/valsartan 5/160 mg versus valsartan/hydrochlorothiazide 160/12.5 mg in patients with essential hypertension uncontrolled by valsartan 160 mg monotherapy

BACKGROUND: To determine whether the effectiveness and safety of fixed-dose combinations (FDCs) of amlodipine orotate/valsartan (AML/VAL) 5/160 mg are noninferior to those of valsartan/hydrochlorothiazide (VAL/HCTZ) 160/12.5 mg in hypertensive patients with inadequate response to valsartan 160 mg mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Youngkeun, Kim, Yongcheol, Chang, Kiyuk, Kim, Weon, Rhee, Moo-Yong, Cha, Kwang Soo, Hyon, Min Su, Shim, Chi Young, Lee, Sung Yun, Kim, Doo Il, Kim, Sang Wook, Lim, Sang-Wook, Han, Kyoo-Rok, Jo, Sang-Ho, Lee, Nae-Hee, Kwan, Jun, Ahn, Taehoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156014/
https://www.ncbi.nlm.nih.gov/pubmed/30212981
http://dx.doi.org/10.1097/MD.0000000000012329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156014/
https://www.ncbi.nlm.nih.gov/pubmed/30212981
http://dx.doi.org/10.1097/MD.0000000000012329

Ejemplares similares